Emcure Pharmaceuticals has allotted 3,33,500 equity shares under ESOS on 22 November 2024. With this allotment, the paid up equity share capital has increased to 18,94,31,847 equity shares of Rs. 10/- each aggregating to Rs. 1,89,43,18,470/']. Powered by Capital Market - Live

In Q2FY25, the drug maker's consolidated revenue from operations stood at Rs 2,002 crore, up 20.4% YoY and 10.3% QoQ. Profit after tax (PAT) was at 202 crore, up 38.2% YoY with PAT margins at 10.1%. EBITDA margins were at 20.8% with EBITDA at Rs 417 crore, up 26.1% YoY and 15.8% QoQ. Gross profit stood at Rs 1,213 crore, up 15.91% YoY and 7.18% QoQ. Gross profit margins were at 60.61% in Q2FY25, lower than 62.94% in Q2FY24 and 62.37% Q1FY25. The quarter saw strong growth especially in the International businesses that grew 25% YoY and 18% QoQ. The Canadian business continued to perform well, achieving a 51% YoY growth, driven by robust growth in its base business and its subsidiary, Mantra. The Rest of the world market business grew 29% YoY aided by strong growth in both ARV and Non-ARV segment. The company continues to see strong traction in its key focus markets. Europe experienced steady growth of 6%, driven by an increase in our base business. Emcure's domestic business grew by over 15% to Rs 933 crore, led by a steady performance in its base business and further aided by Sanofi distribution agreement. Satish Mehta, CEO and managing director, Emcure Pharmaceuticals, said, Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions ' Sanofi partnership in India and Mantra acquisition in Canada ' are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains. Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Shares of Emcure Pharmaceuticals were currently down 1.42% at Rs 1417. It reversed after rising as much as 6.01% in early trade today. Powered by Capital Market - Live

Net profit of Emcure Pharmaceuticals rose 39.83% to Rs 194.57 crore in the quarter ended September 2024 as against Rs 139.15 crore during the previous quarter ended September 2023. Sales rose 20.38% to Rs 2001.98 crore in the quarter ended September 2024 as against Rs 1663.09 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2001.981663.09 20 OPM %19.0319.78 - PBDT370.31271.43 36 PBT273.41201.16 36 NP194.57139.15 40 Powered by Capital Market - Live

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live

Emcure Pharmaceuticals announced the signing of a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries. Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare. Commenting on the development, Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals, said, We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide. Powered by Capital Market - Live

Net profit of Emcure Pharmaceuticals rose 10.48% to Rs 144.08 crore in the quarter ended June 2024 as against Rs 130.41 crore during the previous quarter ended June 2023. Sales rose 16.64% to Rs 1815.14 crore in the quarter ended June 2024 as against Rs 1556.16 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1815.141556.16 17 OPM %18.5319.00 - PBDT301.00258.52 16 PBT207.41191.34 8 NP144.08130.41 10 Powered by Capital Market - Live

Emcure Pharmaceuticals has received upgrade in credit ratings from CRISIL for bank facilities of Rs 2,475.43 crore of the company as under: Long term rating - CRISIL AA-/ Stable Short term rating - CRISIL A1+Powered by Capital Market - Live

Emcure Pharmaceuticals announced that CARE Ratings has upgraded the credit ratings assigned to bank facilities of the company as under: Long term bank facilities (Rs 557.50 crore) - CARE AA-; Stable Long term / short term bank facilities (Rs 1,286 crore) - CARE AA-; Stable/ CARE A1+ Short term bank facilities (Rs 114 crore) - CARE A1+Powered by Capital Market - Live

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live